Revlimid lenalidomide: Phase II data

Data from a Phase II trial in 22 patients showed that Revlimid plus rituximab produced an ORR of 64% after twelve 4-week cycles of treatment. Overall survival (OS) was 95%. In patients ages 65 and older, 71% achieved a response after six 4-week cycles. Data were presented at the American Society of Hematology meeting in New Orleans. ...